Krystal Biotech (NASDAQ:KRYS) Shares Gap Down - Here's Why

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $176.39, but opened at $164.85. Krystal Biotech shares last traded at $165.51, with a volume of 91,893 shares.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Evercore ISI increased their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a research report on Monday, August 12th. William Blair upgraded Krystal Biotech to a "strong-buy" rating in a research note on Friday, August 30th. Chardan Capital raised their target price on Krystal Biotech from $153.00 to $208.00 and gave the stock a "buy" rating in a research report on Monday, August 5th. Citigroup reaffirmed a "neutral" rating and set a $204.00 price target (up previously from $195.00) on shares of Krystal Biotech in a research report on Tuesday, August 6th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Krystal Biotech in a research note on Thursday, August 29th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $196.75.

Krystal Biotech Stock Down 3.1 %

The business's 50-day moving average price is $182.88 and its 200 day moving average price is $180.07. The company has a market capitalization of $4.91 billion, a P/E ratio of 45.51 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.50 by $0.03. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. The firm had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. During the same period last year, the firm earned ($1.25) EPS. The business's quarterly revenue was up 70283900.0% compared to the same quarter last year. Analysts anticipate that Krystal Biotech, Inc. will post 2.88 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 14.10% of the stock is owned by insiders.

Institutional Trading of Krystal Biotech

Several hedge funds have recently added to or reduced their stakes in the business. Janney Montgomery Scott LLC purchased a new position in shares of Krystal Biotech in the first quarter worth about $3,175,000. FORA Capital LLC bought a new stake in Krystal Biotech in the first quarter valued at approximately $1,056,000. Swiss National Bank boosted its stake in shares of Krystal Biotech by 0.8% during the first quarter. Swiss National Bank now owns 36,200 shares of the company's stock valued at $6,441,000 after purchasing an additional 300 shares during the period. Sei Investments Co. grew its holdings in shares of Krystal Biotech by 128.3% in the first quarter. Sei Investments Co. now owns 33,752 shares of the company's stock worth $6,005,000 after purchasing an additional 18,968 shares during the last quarter. Finally, Headlands Technologies LLC bought a new position in shares of Krystal Biotech in the first quarter worth approximately $291,000. 86.29% of the stock is owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).